<DOC>
	<DOCNO>NCT00994097</DOCNO>
	<brief_summary>The main objective study demonstrate superiority progression-free survival ( PFS ) NGR-hTNF add standard chemotherapy regimen ( cisplatin/gemcitabine cisplatin/pemetrexed ) locally advanced ( stage IIIb supraclavicular lymph node metastases malignant pleural pericardial effusion ) , metastatic ( stage IV ) recurrent non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>NGR-hTNF Combination With Standard Chemotherapy Treat Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Eligible patient randomly assign standard chemotherapy regimen plus low-dose ( 0.8 mcg/m^2 ) NGR-hTNF standard chemotherapy alone , centralized randomization process use follow stratification factor : performance status ( 0 vs 1 ) histology ( squamous v non-squamous ) . In arm choice two chemotherapy regimen base histologic subtype : patient squamous histology ( include also generic diagnosis NSCLC without subtype classification ) recommend cisplatin/gemcitabine regimen , patient nonsquamous histology ( include adenocarcinoma large-cell carcinoma ) recommend cisplatin/pemetrexed regimen .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : 1 . Histologically cytologically document inoperable , locally advanced ( stage IIIb supraclavicular lymph node metastases malignant pleural pericardial effusion ) , metastatic ( stage IV ) recurrent NSCLC . Mixed tumor categorize accord predominant cell type . 2 . Age ≥18 year 3 . Life expectancy 3 month 4 . ECOG performance status 01 5 . At least one unidimensional measurable lesion ( per RECIST criterion ) 6 . Adequate baseline bone marrow , hepatic renal function , define follow : Neutrophils &gt; 1.5 x 10^9/L platelet &gt; 100 x 10^9/L Bilirubin &lt; 1.5 x ULN AST and/or ALT &lt; 2.5 x ULN absence liver metastasis AST and/or ALT &lt; 5 x ULN presence liver metastasis Serum creatinine &lt; 1.5 x ULN Creatinine clearance ( estimate accord CockcroftGault formula ) ≥ 50 ml/min 7 . Patients may prior therapy provide follow condition meet : Radiation therapy : washout period 28 day Surgery : washout period 14 day 8 . Patients must give write informed consent participate study Exclusion criterion : 1 . Prior chemotherapy treatment another systemic anticancer agent ( example monoclonal antibody , tyrosine kinase inhibitor ) . 2 . Patients must receive investigational agent study 3 . Patients myocardial infarction within last six ( 6 ) month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication 4 . Uncontrolled hypertension 5 . Prolonged QTc interval ( congenital acquire ) 6 . Patient significant peripheral vascular disease 7 . History evidence upon physical examination CNS disease unless adequately treat ( e.g. , primary brain tumor , brain metastasis , seizure control standard medical therapy , history stroke ) . 8 . Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol 9 . Known hypersensitivity/allergic reaction contraindication human albumin preparation excipients 10 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol 11 . Pregnancy lactation . Patients male female reproductive potential ( i.e . menopausal le 1year surgically sterilize ) must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>NGR-hTNF</keyword>
	<keyword>Randomized control trial</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Pemetrexed</keyword>
	<keyword>Carcinoma , non-small cell lung</keyword>
</DOC>